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Tuberculosis remains a major global health concern, especially in the developing world, and 
monitoring/early detection of the disease relies on low cost technologies that provide rapid 
and accurate results. Mycobacterium tuberculosis is the responsible bacterial pathogen and it 
is currently estimated by the World Health Organisation (WHO), that one quarter of the 
world’s population, mainly in the developing world, is infected with TB. The overall aim of 
this work was to advance a screening electrochemical sensor for label free detection of 
Ag85B, a member of the Antigen 85 complex - major secretary protein of M. Tuberculosis 
and biomarker for disease. An indirect ELISA Ag85B assay was optimised with capture 
antibody and antigen levels determined via a checkerboard titration (0.625µg.ml-1 and 2.5 
µg.ml-1 respectively). Following assay development, crosslinking of the bioreceptor Anti-
Ag85B onto electrochemically deposited gold nanoparticle (AuNP) modified carbon 
electrodes was achieved and Ag85B binding successfully evaluated electrochemically via 
cyclic voltammetry. Following each modification step, ΔEp of a redox probe was monitored 
and overall results show that GCE/AuNP/anti-Ag85B electrochemical transducers are a 
viable method for Ag85B detection, capable of measuring antigen levels < 2.5 μg.mL-1. 
  
This paper is part of the JSS Focus Issue on Solid-State Materials and Devices for Biological and 
Medical Applications.  
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TB is a major global threat and according to the WHO approximately 1.7 million annual 
deaths are attributed to TB [1] with the disease being most prevalent in Asia (58%) and the 
African region (28%). TB is transmitted from person to person through the air and signs and 
symptoms of pulmonary TB include a fever, chronic coughing, weight loss and haemoptysis 
(coughing up blood) [2]. Emergence of multi-drug resistant strains and co-infections with 
human  immunodeficiency (HIV) make for high prevalence and early diagnosis is key for 
disease control. Importantly, TB can exist both as an active and latent disease and the  
Mycobacterium tuberculosis life cycle can be separated into three main stages, latent, 
reactivating and active TB. Active TB is responsible for the symptoms mentioned above 
while patients suffering latent TB show no signs or symptoms of the disease but  are at risk of 
developing the active form of the disease [3]. In order to treat an infection effectively it is 
paramount that accurate and timely diagnosis is performed, preferably at the point of care 
(POC). In high-burden, resource-limited countries sputum smear microscopy is used as a 
primary tool provided there are suitable facilities and a trained microscopist on site with the 
need for patients to make several visits for accurate diagnosis.  The WHO reports that in 
high-burden countries a significant number of patients fail to return to collect their smear 
microscopy results. Xpert MTB/RIF has been reviewed as a rapid test concluding the urgent 
need for new diagnostic strategies [4,5]  and development of POC technologies that should 
allow for rapid diagnosis of a patient at the point where they present themselves, thus 
allowing for treatment to be delivered in a timely and effective way. 
 
The use of antibodies in TB detection have been considered in the development of a POC 
diagnostic tool and there have been numerous serological tests (Rapid-kit test and ELISA 
based test) methods developed as POC diagnostic tools [6,7]. International standards for TB 
have discouraged the use of serological tests as they have been deemed to be inaccurate and 
inconsistent [8]. The limitations experienced in antibody detection methods have led to the 
development of antigen based detection methods. Urine lipoarabinomannan (LAM) antigen 
has been the first and only commercially available antigen detection assay to date. The Alere 
Determine TB-LAM kit POC diagnostic tool was evaluated recently by Sahle et al in relation 
to its sensitivity when used in patients with HIV co-infection [9].  
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It is evident that there is an ever-growing need to contribute to further  on-site diagnostic 
tools based on a range of biomarkers – all of which can contribute to TB screening and 
diagnostics. Antigen 85 complex is the most abundant secretary protein of M. tuberculosis. 
The complex consists of three major proteins, Ag85A (32 kDA), Ag85B (30 kDA) and 
Ag85C (32.5 kDA). Of these three proteins present in the complex, Ag85B is the most 
abundant protein [10].  Ag85A, Ag85B and Ag85C are mycolyl -transferases (family of 
proteins), which are responsible for the synthesis of cell wall components in M. tuberculosis. 
These proteins belong to the CMN (Corynebacterium, Mycobacterium and Norcardia) 
genera. The cell walls, of organisms present in the CMN genera are comprised of 
interconnected peptidoglycan and polysaccharide-mycolate complex and are characterised by 
mycolic acid present on the surface of the cell wall. Mycolic acids are long chain fatty acids 
that are present in the cell wall envelope and are responsible for pathogenesis and survival of 
the organism in a host cell. The Mycobacterium cell envelope contains mycolic acid 
comprising of ~60-90 carbons [11].  A study by Zhang et al examined new biomarkers 
including Ag85B in the serodiagnosis between active and latent TB infection,  concluding 
that a combined test of multiple M. Tuberculosis secreted proteins may be used as screening 
antigens for active TB for early diagnosis or screening of h risk population [1]. Other studies 
have confirmed the presence of the Ag85 complex in the serum of patients, offering a 
trustworthy TB diagnosis without false positives of other non-TB diseases [12]. 
 
The focus of this work was to establish (for the first time) the feasibility of an 
electrochemical assay for Ag85B based on immunoassay development followed by antibody-
antigen binding studies with the aid of cyclic voltammetry. While immunoassays are a 
fundamental tool for clinical analysis, they require the need for highly skilled specialised staff 
and the use of desktop equipment in a laboratory setting for generation of optimum results. 
However, in most remote areas where critical analysis is crucial, often analysis cannot be 
performed due to the lack of trained personnel or suitable facilities. The development of 
miniaturised analytical devices such as immunosensors can overcome the need for skilled 
personnel and use of expensive laboratory equipment.  Electrochemical immunosensors are 
of particular interest due to their high sensitivity, low cost, miniaturisation and simplicity 
during fabrication [13]. Wang et al. described the detection of LAM antibody for the 
determination of TB. Detection was performed at disposable screen printed electrodes using 
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AuNPs labelled staphylococcal protein (Au-SPA) as an electrochemical tag for detection of 
LAM antibody (anti-LAM). The immunosensor under optimal conditions obtained a linear 
concentration response to anti-LAM from 15.6 to 1000 ng.ml-1 with a detection limit of 5.3 
ng.ml-1 [14]. Dionani et al examined an ESAT-6 immunoelectrochemical biosensor for TB 
with the aid of square wave voltammetry and [Fe(CN)6 
3-] as redox probe [15] with detection 
limit 7 mg mL-1.  Liu et al. developed an immunosensor for detection of Mycobacterium 
DNA in sputum samples. The sensor consisted of a glassy carbon electrode (GCE) modified 
with reduced graphene oxide-gold nanoparticles (rGO-AuNPs) to act as a sensing platform. 
Gold nanoparticle-polyaniline composites (Au-PANI) were used as tracer label for 
amplification for the detection of Mycobacterium DNA [16]. 
 
In order to address the lack of electrochemical immunosensing approaches based on the 
promising Ag85 protein complex, and to advance electroanalytical screening tools based on 
suitable TB biomarker measurement we present  (a) indirect ELISA immunoassay 
development for Ag85B and  (b) a preliminary assessment of the use of voltammetry as an 
electrochemical screening tool for the presence of Ag85B with facile format making it 
suitable for  use at the  point of care. 
Materials and Methods 
Potassium ferricyanide (K3Fe(CN)6), potassium ferrocyanide (K4Fe(CN6), gold (III) chloride 
trihydrate (HAuCl4.3H2O, ≥99% purity), 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide, 
methiopropamine (MPA), N-Hydroxysuccinimide (NHS), phosphate buffered saline (PBS  
0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride, pH 
7.4) and PBS with Tween-20 (PBST), anhydrous sodium carbonate, bovine serum albumin 
(BSA ≥ 96%), 3,3’,5,5’-tetramethylbenzidine (TMB liquid substrate for ELISA) were used as 
received from Sigma Aldrich. Recombinant Mycobacterium tuberculosis Ag85B protein, 
Antigen 85B (ab83471 – 50 μg), rabbit polyclonal to Mycobacterium tuberculosis (ab43019 – 
100 μl) and Goat Anti-Rabbit IgG H&L (HRP- ab97051-1mg) were purchased from Abcam 
and used as supplied. 
Instrumentation  
All electrochemical synthesis and measurements were performed via the use of CH 
Instruments Inc. CH660C electrochemical potentiostat. A three electrode system was used 
consisting of a working electrode, glassy carbon electrode (GCE), an Ag/AgCl reference 
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electrode and a platinum wire counter electrode. UV-Visible analysis for optical ELISA 
measurements was performed on a BioTek Synergy H1 Hybrid plate reader. 
Procedures 
Checkerboard Titration 
A checkerboard titration was performed to determine the optimum concentration for Anti-
Ag85B [17] Initially, 50 μl of carbonate coating buffer (pH 9.6) was added to each microwell 
from column 2 to 12 of the plate. Serial dilution of Ag85B was performed by adding 100 μl 
of stock Ag85B (10 μg.ml-1) to each microwell of column 1 (Figure 1 A). A 2-fold dilution of 
Ag85B was performed by dispensing 50 μl from each well of column 1 into each well of 
column 2. The antigen solution in column 2 was then mixed with carbonate buffer present 
from the initial coating step by drawing the solution in and out of the multichannel pipette 
(x5) to ensure adequate mixing. This transfer and mixing process continued from column 2 
until column 11. After mixing of the solution in column 11, 50 μl of the solution was 
dispensed into waste with column 12 only receiving coating buffer, thus acting as a control 
line as no Ag85B is present in column 12. Antigen concentrations from column 1 to 11 were 
10, 5, 2.5, 1.25, 0.63, 0.32, 0.16, 0.08, 0.04, 0.02 and 0.01 μg.ml-1 respectively. 
 
The Ag85B coated plate was then wrapped in foil and incubated at 37oC for 1 hr. in a heated 
oven. The plate was then removed, emptied and vigorously washed 3 times with PBST and 
air dried before blocking the plate. Blocking of unoccupied sites of the plate was performed 
by dispensing 100 μl of 1% BSA in PBST to each well and incubating at 37oC for 1 hr. The 
plate was removed once more and washed using PBST and left to air dry for further use. 
 
Serial dilution for Anti-Ag85B was performed by adding 100 μl of stock Anti-Ag85B (10 
μg.ml-1) to all microwells of row A on the plate (Figure 1 B). 50 μl of 1% BSA-PBST was 
added to the remaining row, B to H. A 2-fold dilution of Anti-Ag85B was performed by 
dispensing 50 μl of Anti-Ag85B from each well of row A into each well of row B. The 
antibody solution in row B was then mixed with 1% BSA-PBST present in row B by drawing 
the solution in and out of the multichannel pipette (x5) to ensure adequate mixing. This 
transfer and mixing process continued from row B to row G. After the final transfer and 
mixing process in row G, 50 μl of the solution was removed and dispensed into waste with 
row H only receiving 1% BSA-PBST, thus acting as a control line as no Anti-Ag85B is 
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present in row H. Antibody dilutions from row A to H were 1/100, 1/200, 1/400, 1/800, 
1/1600, 1/3200, 1/6400 and 0 respectively. 
 
The Anti-Ag85B coated plate was foil wrapped and incubated at 37oC for 1 hr. after which it 
was vigorously washed 3 times with PBST. 100 μl of Goat-rabbit IgG HRP-labelled 
conjugate (0.1 μg.ml-1) was added to each microwell of the plate and incubated for 1 hr. at 
37oC. The plate was removed and washed a further 3 times using PBST before 100 μl of 
TMB was added to each well and incubated for 15 minutes at room temperature. The enzyme 
reaction was quenched by the addition of 100 μl of 1 M HCl to each well of the plate, which 
prevents colour saturation and changes the reaction colour from blue to yellow. The optical 
density was then measured at 450 nm. 
 
Scheme 1 shows the overall ELISA format employed. The Anti-Ag85B coated plate was foil 
wrapped and incubated at 37oC for 1 hr. after which it was vigorously washed 3 times with 
PBST. 100 μl of Goat-rabbit IgG HRP-labelled conjugate (0.1 μg.ml-1) was added to each 
microwell of the plate and incubated for 1 hr. at 37oC. The plate was removed and washed a 
further 3 times using PBST before 100 μl of TMB was added to each well and incubated for 
15 minutes at room temperature. The enzyme reaction was quenched by the addition of 100 
μl of 1 M HCl to each well of the plate, which prevents colour saturation and changes the 
reaction colour from blue to yellow. The optical density was then measured at 450 nm. 
Development of nano gold modified electrode Immunosensor 
Prior to AuNP deposition, a GCE electrode was vigorously polished in alumina slurry (1.0, 
0.3 and 0.05 µm) followed by continuous cycling in 0.5 M H2SO4 until reproducible currents 
were observed. The electrode was placed in a three-electrode cell containing a solution of 2.5 
mM HAuCl4.3H2O in 0.1 M NaNO3 and cycled over the potential window 0.0 V to +1.0 V 
for a total of 10 cycles [18]. The electrode was then vigorously rinsed with deionised water to 
remove any remaining precursor ions. The electrode was labelled GCE/AuNP. The 
GCE/AuNPs was then immersed in an aqueous 0.01 MPA solution overnight and washed 
with deionised water to remove any remaining MPA solution. Activation of the carboxylic 
groups of the thiol linker, now present on the surface of the AuNPs was performed by 
immersing the modified electrode for 2 hours in an ethanolic solution of 0.01 M EDC/0.01 M 
NHS (Scheme 2) based on a previously reported approach by our group [18]. 
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Detection of Ag85B  
Detection of Ag85B was performed at the GCE/AuNP modified electrode. 5 μl of Anti-
Ag85B (0.625 μg.ml-1) was dispensed onto the surface of the GCE/AuNP and incubated at 
37oC for 1 hr. after which the GCE/AuNP was rinsed with deionised water to remove any 
excess Anti-Ag85B. The GCE/AuNP/Anti-Ag85B was then dried under argon gas. 5 μl of 
1% BSA-PBST was then dispensed onto the surface of the GCE/AuNP/Anti-Ag85B to 
prevent non-specific binding and incubated for 1 hr. at 37oC. The GCE/AuNP/Anti-
Ag85B/BSA was rinsed and dried with argon gas. 5 μl of Ag85B (2.5 μg.ml-1) was then 
dispensed onto the surface of the GCE/AuNP/AntiAg85B/BSA and incubated for 1 hr. at 
37oC. Ag85B binding was then accessed electrochemically using a redox probe. 
 
Results and Discussion 
ELISA Development 
Checkerboard Titration for Ag85B Indirect ELISA Development 
A checkerboard titration (Figure 2) was performed to identify the optimum concentration of 
Anti-Ag85B for the development of an indirect ELISA assay. A 15-minute enzyme-substrate 
reaction was performed by reacting Goat-rabbit IgG HRP-labelled conjugate with TMB and 
the subsequent optical density is measured at 450 nm. A plateau region was expected where 
little change in optical density is observed due to the fact that different combinations of 
Ag85B and Anti-Ag85B concentrations decrease across the plate.  
An initial 1/100 dilution of Anti-Ag85B (1 mg.ml-1) was carried out yielding a stock 
concentration of 10 μg.ml-1. The stock Anti-Ag85B (10 μg.ml-1) was then serially diluted 
from row B to G, yielding concentrations of 5, 2.5, 1.25, 0.63, 0.32 and 0.16 μg.ml-1 
respectively. Figure 3-10 illustrates the result for optical densities recorded for Anti-Ag85B 
in response to Ag85B. At high concentrations of Anti-Ag85 up to 1/400 dilution, saturation 
of the antibody-antigen system was observed with concentrations of Ag85B less than 2 
μg.ml-1. Selection of the optimum antibody concentration was based on which combination of 
Anti-Ag85B and Ag85B gave 75% of the absorbance plateau [20] Singh et al  This was 
achieved with Anti-Ag85B using a dilution of 1:1600 to give a concentration of 0.625 μg.ml-
1. 
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Development of an Ag85B Immunosensor based on AuNPs 
Electrochemical deposition of AuNPs at a GCE electrode was performed by cyclic 
voltammetry. Figure 3 shows a cyclic voltammogram for AuNPs deposition, where Au(III) 
was reduced to Au(0) at 0.39 V vs. Ag/AgCl. The shift in peak position observed after 10 
cycles, from 0.39 V to 0.7 V confirmed AuNPs deposition [18]. 
 
AuCl4 + 3e
- ⇌ Au (0) + 4Cl- 
 
AuNPs characterisation was performed by cycling the GCE/AuNPs in 0.5 M H2SO4, to ensure 
that AuNP deposition was successful. Figure 3 illustrates characteristic features of AuNPs in 
acid with gold oxide formation and reduction present at 1.3 V and 0.9 V respectively [21,22]. 
 
The modification process for the GCE/AuNPs immunosensor was measured by examining 
the electrode in a solution containing 5 mM [Fe(CN)6]
3-/4-
 (1:1) redox couple in 0.01 M PBS 
(pH 7.4) over the range 0.8 V to -0.2 V at a scan rate of 0.1 V.s-1. Figure 4 shows the 
influence of AuNPs deposition on the redox couple. It was observed that oxidation (115.20 
μA) and reduction (-110.40 μA) currents increased and a shift in ΔEp (119.20 mV) occurred. 
It was expected that AuNPs deposition would result in an increase in current in comparison to 
bare GCE as nanoparticles provide a high surface to volume ratio thus enhancing the rate of 
electron transfer [18,23]. 
 
Following AuNP deposition the effect of the self-assembled monolayer of MPA was 
examined. Figure 5 illustrates that MPA inhibits electron transfer of the redox probe as a 
decrease in peak oxidation (84.69 μA) and reduction currents (-82.81 μA) as well as a large 
change in ΔEp (from 119.20 mV to 240 mV) was observed [18]. Immobilisation of Anti-
Ag85B onto the surface of the newly formed GCE/AuNPs/MPA was performed by 
dispensing 5 μl of Anti-Ag85B (0.625 μg.ml-1) onto the surface of the GCE/AuNPs/MPA 
following activation of the carboxylic thiol linker  and incubated for 1 hr. at 37oC. The 
immobilisation of Anti-Ag85B resulted in a decrease in oxidation current (76.43 μA) as well 
as shifts in ΔEp (from 240 mV to 265.50 mV) values as seen in Figure 6 suggesting that Anti-
Ag85B was successfully immobilised onto the surface of the GCE/AuNPs/MPA resulting in 
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To prevent non-specific binding and to block any remaining active sites 5 μl of 1% BSA-
PBST was dispensed onto the surface of the GCE/AuNPs/MPA/Anti-Ag85B and incubated at 
37oC for 1 hr. Figure 7 shows the largest change in ΔEp (from 265.50 mV to 487 mV) and 
further decreases in oxidation (60.62 μA) and reduction currents (-64.87 μA) following 
deposition of 1% BSA-PBST. 
 
Electrochemical detection of Ag85B at GCE/AuNPs/MPA/Anti-Ag85B/BSA was examined 
by depositing 5 μl of Ag85B (2.5 μg.ml-1) and incubating for 1 hr. at 37oC. Figure 8 
illustrates the resulting effect of Ag85B on the GCE/AuNPs/MPA/Anti-Ag85B/BSA sensor 
using a redox probe. A further decrease in oxidation (54.06 μA) and reduction current (-56.88 
μA) was observed as well as a shift in ΔEp (from 487 mV to 499.40 mV) following the 
introduction of 2.5 μg.ml-1 Ag85B.  The changes in ΔEp and peak currents were attributed to 
Ag85B causing resistance to electron transfer, thus suggesting that significant binding has 
occurred between Anti-Ag85B and Ag85B. 
 
 
The results obtained for each modification step of the Ag85B immunosensor are shown in 
Table I They illustrate the change in Iox ,Ired and ΔEp following each modification step of the 
Ag85B immunosensor as measured via a redox probe.  
 
From Table 1 and Figure 9 it was observed that with each modification step, changes to the 
oxidation and reduction current peaks and ΔEp were observed. AuNPs deposition resulted in 
changes to peak currents and a shift in ΔEp compared to a bare GCE due to the high surface to 
volume ratio of the nanoparticles. The self-assembled monolayer of MPA resulted in 
decrease to peak currents and a large shift in ΔEp due to MPA inhibiting electron transfer. 
Immobilisation of Anti-Ag85B to the Ag85B immunosensor was confirmed by further 
changes to peak currents and shifts in ΔEp. 5 μl of 1% BSA-PBST was introduced to the 
sensor to prevent non-specific binding of Anti-Ag85B and resulted in further decrease to 
peak currents and a large change (as expected) in ΔEp (222 mV vs Ag/AgCl). Finally, Ag85B 
binding (2.5 μg.ml-1 ) was confirmed by observing decreases in peak current and an increase 
in ΔEp (13 mV) over that of the BSA effect for n=3 electrodes.  
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The concentration of Ag85B detected by the Ag85B immunosensor in this study was 2.5 
μg.ml-1. When referring to the literature, concentrations of Ag85B have been detected ranging 
from the femtogram (fg) to the μg level. Kim et al. developed a sandwich assay for detection 
of Ag85B using quantum dots and gold nanorods. The sensor had a linear range from 0.013 
to 1 ng.ml-1 with a limit of detection (LOD) of 0.013 ng.ml-1 [24]. Saengdee et al. detected 
Ag85B over the linear range of 0.12 μg.ml-1 to 1.0 μg.ml-1 [25].  When comparing the Ag85B 
immunosensor in this study to that of sensors found in the literature the LOD for this sensor 
is in the upper limits for Ag85B detection at this stage of the work. From further 
investigations into the literature there appears to be no predetermined physiological 
concentration for Ag85B in TB patients and it also may be related to clinical sample type. 
 
Table 2 presents a comparison of analytical performance for reported Ag85B assay detection 
methods and sensors, with respect to current literature. The majority of these approaches are 
laboratory confined while the immunosensing device proposed in this work has the 
advantages of providing a portable, low-cost platform for the rapid detection of Ag85B 
although; further studies to validate analytical performance are required. Additionally, the 
proposed device has significant novelty due to there being very limited reports of biosensors 




The double burden of TB and HIV remains a challenge to medicine and public health in 
developing countries with disease control dependant on prompt diagnostics and therapeutic 
intervention. Though further work is required and planned for, the methodology developed 
for Ag85B and presented here is promising, filling a knowledge gap in relation to its viability 
as a rapid diagnostic tool. Assay development realised a working ELISA method for Ag85B 
with optimal levels of bioreagents suitable for transfer onto an electrochemical transducer for 
the first time. Functionalisation of AuNP and subsequent coupling to anti-Ag85B antibodies 
realised a simple effective receptor surface with signal discrimination enabled with the 
assistance of a redox probe. The successful use of AuNPs as a platform for detecting Ag85B 
will rely on quantitative electrochemical studies which form the next step to evaluate 
sensitivity and limits of detection. Electrochemical impedance spectroscopy and/or 
differential pulse voltammetry will play a role in this regard. Further investigations into the 
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fabrication and miniaturisation of an AuNPs based immunosensor for Ag85B detection may 
be advanced with the aid of screen printed transducers integrated with lateral flow 
membranes for clinical sample processing, coupled with micro-potentiostat control enabling 
portable operation and deployment.  
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Fig. 1 a Checkerboard titration schematic for serial dilution of antigen Ag85B. Carbonate 
coating buffer (50 μl) was dispensed in all columns except column 1. Stock Ag85B (10 
μg.ml-1) was dispensed into column 1 (100 μL) and serial diluted from column 1 to 11. b 
Checkerboard titration schematic for serial dilution of antibody Ag85B. 1% BSA-PBST (50 
μl) was dispensed in all rows except row H. Stock Anti-Ag85B (10 μg.ml-1) was dispensed 
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Scheme 1 a. Oxidation of TMB in the presence of H2O2 resulting in the formation of 
3,3’,5,5’-tetramethlybenzidine diimine, which is blue in colour b. schematic representation of 
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Scheme 2 a. Schematic representation of GCE modification process with AuNPs. b. 
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Fig. 2 Checkerboard titration plot showing optical density intensity of TMB at 450 nm. 
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Fig. 3 Cyclic voltammogram for gold nanoparticles with characteristic Au oxide formation 
(I) at 1.3 V and reduction peak (II) of Au present at 0.9 V vs. Ag/AgCl in 0.5 M H2SO4 at 
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Fig. 4 Cyclic voltammogram of (a) bare GCE and (b) GCE/AuNP in a solution of 5 mM 
[Fe(CN)6]







Fig. 5 Cyclic voltammogram of (a) bare GCE, (b) GCE/AuNPs, (c) GCE/AuNPs/MPA in a 
solution of 5 mM [Fe(CN)6]
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Fig. 6 Cyclic voltammogram of (a) bare GCE, (b) GCE/AuNPS, (c) GCE/AuNPs/MPA, (d) 
GCE/AuNPS/MPA/Anti-Ag85B in a solution of 5 mM [Fe(CN)6 ]
3-/4- and 0.01 M PBS (pH 








Fig. 7 Cyclic voltammogram of (a) bare GCE, (b) GCE/AuNPS, (c) GCE/AuNPs/MPA, (d) 
GCE,AuNPS/MPA/Anti-Ag85B, (e) GCE/AuNPS/MPA/Anti-Ag85B/1% BSA in a solution 
of 5 mM [Fe(CN)6]
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Fig. 8 Cyclic voltammogram of (a) bare GCE, (b) GCE/AuNPs, (c) GCE/AuNPs/MPA, (d) 
GCE/AuNPS/MPA/Anti-Ag85B, (e) GCE/AuNPs/MPA/Anti-Ag85B/1% BSA, (f) 
GCE/AuNPs/MPA/Anti-Ag85B/1% BSA/Ag85B in a solution of 5 mM [Fe(CN)6]
3-/4- and 
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Table 1 Iox ,Ired and ΔEp values of [Fe(CN)6 ]
3-/4-
 redox couple for range of electrode 
modifications. 
Electrode  Iox (μA) ΔIox 
(μA) 
Ired (μA) ΔIred 
(μA) 
ΔEp(mV) 
GCE 99.01 - -98.86 - 134.50 
GCE/AuNPs 115.20 16.19 -110.40 11.54 119.80 
GCE/AuNPs/MPA 84.69 30.51 -82.81 27.59 240 
GCE/AuNPs/MPA/Anti-
Ag85B 
76.43 8.26 -81.35 1.46 265.50 
GCE/AuNPs/MPA/Anti-
Ag85B/BSA 
60.62 15.81 -64.87 16.48 487 
GCE/AuNPs/MPA/Anti-
Ag85B/BSA/Ag85B 









Fig. 9 Bar chart illustrating the change in ΔEp, (a) GCE (b) GCE/AuNPs, (c) 
GCE/AuNPs/MPA, (d) GCE/AuNPs/MPA/Anti-Ag85B, (e) GCE/AuNPs/MPA/Anti-
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